Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals has disclosed Other Non-Current Assets across 15 years of filings, most recently posting $11.6 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $11.6 million, up 12.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (up 12.24% YoY), and the FY2025 annual result was $13.7 million, up 12.16% from the prior year.
• Other Non-Current Assets came in at $11.6 million for Q1 2026 at Ani Pharmaceuticals, down from $13.7 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $16.1 million in Q3 2023 to a low of $2.4 million in Q1 2022.
• The 5-year median for Other Non-Current Assets is $12.1 million (2023), against an average of $11.2 million.
• Peak annual rise in Other Non-Current Assets reached 415.24% in 2022, while the deepest fall reached 51.32% in 2022.
• Ani Pharmaceuticals' Other Non-Current Assets stood at $11.4 million in 2022, then advanced by 6.26% to $12.1 million in 2023, then climbed by 1.23% to $12.2 million in 2024, then advanced by 12.16% to $13.7 million in 2025, then fell by 15.55% to $11.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $11.6 million (Q1 2026), $13.7 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.